IBDEI0YI ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17147,2)
 ;;=^330079
 ;;^UTILITY(U,$J,358.3,17148,0)
 ;;=282.61^^111^1075^18
 ;;^UTILITY(U,$J,358.3,17148,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17148,1,1,0)
 ;;=1^282.61
 ;;^UTILITY(U,$J,358.3,17148,1,8,0)
 ;;=8^Hb-SS Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,17148,2)
 ;;=^330078
 ;;^UTILITY(U,$J,358.3,17149,0)
 ;;=282.63^^111^1075^51
 ;;^UTILITY(U,$J,358.3,17149,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17149,1,1,0)
 ;;=1^282.63
 ;;^UTILITY(U,$J,358.3,17149,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,17149,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,17150,0)
 ;;=282.64^^111^1075^50
 ;;^UTILITY(U,$J,358.3,17150,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17150,1,1,0)
 ;;=1^282.64
 ;;^UTILITY(U,$J,358.3,17150,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,17150,2)
 ;;=^329911
 ;;^UTILITY(U,$J,358.3,17151,0)
 ;;=282.68^^111^1075^38
 ;;^UTILITY(U,$J,358.3,17151,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17151,1,1,0)
 ;;=1^282.68
 ;;^UTILITY(U,$J,358.3,17151,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,17151,2)
 ;;=^329912
 ;;^UTILITY(U,$J,358.3,17152,0)
 ;;=282.69^^111^1075^37
 ;;^UTILITY(U,$J,358.3,17152,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17152,1,1,0)
 ;;=1^282.69
 ;;^UTILITY(U,$J,358.3,17152,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,17152,2)
 ;;=^330081
 ;;^UTILITY(U,$J,358.3,17153,0)
 ;;=282.7^^111^1075^34
 ;;^UTILITY(U,$J,358.3,17153,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17153,1,1,0)
 ;;=1^282.7
 ;;^UTILITY(U,$J,358.3,17153,1,8,0)
 ;;=8^Oth Hemoglobinopathies
 ;;^UTILITY(U,$J,358.3,17153,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,17154,0)
 ;;=282.8^^111^1075^40
 ;;^UTILITY(U,$J,358.3,17154,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17154,1,1,0)
 ;;=1^282.8
 ;;^UTILITY(U,$J,358.3,17154,1,8,0)
 ;;=8^Oth Spec Hereditary Hemolytic
 ;;^UTILITY(U,$J,358.3,17154,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,17155,0)
 ;;=283.10^^111^1075^31
 ;;^UTILITY(U,$J,358.3,17155,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17155,1,1,0)
 ;;=1^283.10
 ;;^UTILITY(U,$J,358.3,17155,1,8,0)
 ;;=8^Non-autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,17155,2)
 ;;=^294004
 ;;^UTILITY(U,$J,358.3,17156,0)
 ;;=283.11^^111^1075^22
 ;;^UTILITY(U,$J,358.3,17156,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17156,1,1,0)
 ;;=1^283.11
 ;;^UTILITY(U,$J,358.3,17156,1,8,0)
 ;;=8^Hemolytic-uremic Syndrome
 ;;^UTILITY(U,$J,358.3,17156,2)
 ;;=^293663
 ;;^UTILITY(U,$J,358.3,17157,0)
 ;;=285.0^^111^1075^52
 ;;^UTILITY(U,$J,358.3,17157,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17157,1,1,0)
 ;;=1^285.0
 ;;^UTILITY(U,$J,358.3,17157,1,8,0)
 ;;=8^Sideroblastic Anemia
 ;;^UTILITY(U,$J,358.3,17157,2)
 ;;=^7204
 ;;^UTILITY(U,$J,358.3,17158,0)
 ;;=285.3^^111^1075^9
 ;;^UTILITY(U,$J,358.3,17158,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17158,1,1,0)
 ;;=1^285.3
 ;;^UTILITY(U,$J,358.3,17158,1,8,0)
 ;;=8^Antineoplastic Chemo Ind Anemia
 ;;^UTILITY(U,$J,358.3,17158,2)
 ;;=^338232
 ;;^UTILITY(U,$J,358.3,17159,0)
 ;;=285.8^^111^1075^39
 ;;^UTILITY(U,$J,358.3,17159,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17159,1,1,0)
 ;;=1^285.8
 ;;^UTILITY(U,$J,358.3,17159,1,8,0)
 ;;=8^Oth Spec Anemia
 ;;^UTILITY(U,$J,358.3,17159,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,17160,0)
 ;;=283.2^^111^1075^21
 ;;^UTILITY(U,$J,358.3,17160,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17160,1,1,0)
 ;;=1^283.2
 ;;^UTILITY(U,$J,358.3,17160,1,8,0)
 ;;=8^Hemolytic d/t Hemolysis
 ;;^UTILITY(U,$J,358.3,17160,2)
 ;;=^55770
 ;;^UTILITY(U,$J,358.3,17161,0)
 ;;=280.0^^111^1075^27
